A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

• Status: Terminated
• Trial end date: 2018-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Geographic atrophy due to age-related macular degeneration in the study eye

• Visual acuity better than or equal to 20/125 Snellen equivalent in the study eye and 20/200 Snellen equivalent in the fellow eye.

Exclusion Criteria:

• Cataract surgery or Laser-Assisted in situ Keratomileusis (LASIK) in the study eye in the last 3 months

• Infections in either eye in the last 3 months